Literature DB >> 1585490

Endothelial cell preservation using organ storage solutions.

W A Killinger1, D B Dorofi, B A Keagy, G Johnson.   

Abstract

The development of organ preservation solutions has been primarily accomplished in whole organ animal models. This study examines the toxicity of commonly used organ preservation solutions on endothelial cells in vitro. Primary human umbilical-vein endothelial cell cultures were incubated at 4 degrees C in solutions of 0.9% saline (NS), EuroCollins, ViaSpan (Belzer UW) (VIA), or Hank's balanced salts with 5% polyethylene glycol (PEG). Endothelial cell viability was ascertained by colormetric measurement of mitochondrial reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to purple 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan. After exposure to hypothermic storage, cells were incubated at 37 degrees C in media with MTT, and the amount of reduced formazan present was quantified using a micro-ELISA spectrophotometer. Higher absorbance values were indicative of better cellular preservation. Cells stored in PEG displayed the highest viability at all time periods. ViaSpan provided better cellular protection than EC at longer storage intervals. This model allows for rapid assessment of preservation-induced endothelial cell injury and may aid development of improved storage techniques.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1585490     DOI: 10.1097/00007890-199205000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Ex vivo perfusion of mid-to-late-gestation mouse placenta for maternal-fetal interaction studies during pregnancy.

Authors:  Nick Goeden; Alexandre Bonnin
Journal:  Nat Protoc       Date:  2012-12-13       Impact factor: 13.491

2.  In vitro modeling of nonhypoxic cold ischemia-reperfusion simulating lung transplantation.

Authors:  Monica Casiraghi; Jason R Tatreau; John B Abano; John W Blackwell; Larry Watson; Keith Burridge; Scott H Randell; Thomas M Egan
Journal:  J Thorac Cardiovasc Surg       Date:  2009-09       Impact factor: 5.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.